[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100465325":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":36,"centralContacts":40,"locations":27,"responsibleParty":48,"collaborators":51,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":27,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":27,"enrollmentInfo":64,"targetDuration":27,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":27,"overallStatus":73,"whyStopped":27,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":27},{"fullName":5,"class":6},"New York State Psychiatric Institute","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Telehealth buprenorphine induction and maintenance","EXPERIMENTAL","Sublingual (SL) Buprenorphine and a medical management protocol adapted to the unique needs of home-based telehealth for MOUD using SL buprenorphine",[13,14],"Drug: Buprenorphine SL","Other: Telehealth",{"label":16,"type":17,"description":18,"interventionNames":19},"Standard in-person SL buprenorphine induction and maintenance","ACTIVE_COMPARATOR","In-person induction and maintenance dosing of sublingual buprenorphine, or MOUD as usual.",[13,20],"Other: In-person treatment as usual",[22,28,32],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Buprenorphine SL","Up to 24 mg per day",[16,9],null,{"type":6,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Telehealth","Telehealth MOUD, utilizing a standardized protocol for each healthcare provider session",[9],{"type":6,"name":33,"description":34,"armGroupLabels":35,"otherNames":27},"In-person treatment as usual","in-person induction and maintenance dosing of sublingual buprenorphine, or MOUD as usual.",[16],[37],{"name":38,"affiliation":5,"role":39},"Christina Brezing, MD","PRINCIPAL_INVESTIGATOR",[41,45],{"name":38,"role":42,"phone":43,"phoneExt":27,"email":44},"CONTACT","646-774-6132","cb3108@columbia.edu",{"name":46,"role":42,"phone":47,"phoneExt":27,"email":27},"Elizabeth Martinez","646-774-8181",{"type":39,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"Christina Ann Brezing","Assistant Professor of Psychiatry",[52],{"name":53,"class":54},"National Institute on Drug Abuse (NIDA)","NIH","100465325","phase-2-sublingual-buprenorphine-through-telemedicine-vs-in-person-care-as-usual-100465325",false,"NCT05339256","Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual","A Randomized, Controlled Trial of Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual in the Treatment of Opioid Use Disorder","Inclusion Criteria:\n\n* meet DSM-5 criteria for OUD\n* Voluntarily seeking buprenorphine treatment for OUD\n* Able to provide informed consent and comply with study procedures\n\nExclusion Criteria:\n\n* Meeting DSM-5 criteria for substance use disorder other than opioid as the primary diagnosis that would compromise safety of participation in the trial as determined by the study physician, such as an alcohol or sedative hypnotic use disorder that requires detoxification\n* Having a comorbid psychiatric diagnosis that might interfere with participation or make participation hazardous, such as a psychotic disorder including schizophrenia or schizoaffective disorder\n* Concurrent methadone, buprenorphine, or vivitrol maintenance treatment\n* Known history of allergy, intolerance, or hypersensitivity to candidate medication (buprenorphine)\n* Pregnancy, lactation, or failure to use adequate contraceptive methods in female patients\n* Unstable medical conditions, such as severe hepatic, renal, or cardiovascular disease, which might make participation\n* Current or recent history history of significant violent or suicidal behavior or risk for suicide or homicide\n* Legally mandated to substance use disorder treatment.","ALL","18 Years",{"count":65,"type":66},50,"ESTIMATED","INTERVENTIONAL",[69],"PHASE2","This study will compare in-person induction and maintenance dosing of sublingual buprenorphine to induction and maintenance dosing of sublingual buprenorphine through comprehensive telehealth sessions and telehealth medication for opioid use disorder (MOUD).",[72],"Opioid Use Disorder","NOT_YET_RECRUITING","2026-04-06",{"date":76,"type":77},"2026-04-13","ACTUAL",{"date":79,"type":66},"2026-06-01",{"date":81,"type":66},"2026-12-31",{"name":5,"class":6}]